-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Ws+CHdkfqyzAxUyWLjr9Kjcv3dwINtUG0cUugaj512lBG7nYPHBSHQS354tBo6sg
 MKPof3GUPgILd6lePMMszA==

<SEC-DOCUMENT>0000842023-07-000024.txt : 20070807
<SEC-HEADER>0000842023-07-000024.hdr.sgml : 20070807
<ACCEPTANCE-DATETIME>20070807102642
ACCESSION NUMBER:		0000842023-07-000024
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20070807
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070807
DATE AS OF CHANGE:		20070807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TECHNE CORP /MN/
		CENTRAL INDEX KEY:			0000842023
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				411427402
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17272
		FILM NUMBER:		071030266

	BUSINESS ADDRESS:	
		STREET 1:		614 MCKINLEY PL N E
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
		BUSINESS PHONE:		6123798854

	MAIL ADDRESS:	
		STREET 1:		614 MCKINLEY PLACE NE
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>k8q.txt
<DESCRIPTION>8-K
<TEXT>
                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT

                  PURSUANT TO SECTION 13 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): August 7, 2007

                            TECHNE CORPORATION
             (Exact Name of Registrant as Specified in Charter)


       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                614 Mckinley Place NE
                   Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))


<PAGE>



Item 2.02  Results of Operations and Financial Condition

A copy of the press release issued by Techne Corporation on August 7, 2007,
describing the results of operations for the quarter and fiscal year ended
June 30, 2007 and its financial condition as of June 30, 2007, is
attached hereto as Exhibit 99.1.

Segment information for Techne Corporation for the quarter and fiscal year
ended June 30, 2007 which has been included on Techne Corporation's
website (www.techne-corp.com), is attached hereto as Exhibit 99.2.

The information in this Form 8-K and the Exhibits attached hereto shall not
be deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such filing.


Item 9.01 Financial Statements and Exhibits

     (d) Exhibits

         99.1 Press Release dated August 7, 2007.

         99.2 Segment information for the quarter and fiscal year ended
              June 30, 2007.






                            SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: August 7, 2007                 TECHNE CORPORATION
                                      By: /s/ Thomas E. Oland
                                      ---------------------------
                                      Name: Thomas E. Oland
                                      Title: President and Chief
                                        Executive Officer



                          EXHIBIT INDEX

    Exhibit No. Description
    ----------- -----------
       99.1     Press release of Techne Corporation dated August 7, 2007.

       99.2     Segment information for Techne Corporation for the quarter
                and fiscal year ended June 30, 2007.

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>press807.txt
<DESCRIPTION>EARNINGS RELEASE DATED AUGUST 7, 2007
<TEXT>
              TECHNE CORPORATION RELEASES UNAUDITED FOURTH QUARTER
                         RESULTS FOR FISCAL YEAR 2007

Minneapolis/August 7, 2007/--Techne Corporation's (NASDAQ: TECH) consolidated
net earnings for the quarter ended June 30, 2007 increased 17.6% to $22.9
million or $.58 per diluted share compared with $19.5 million or $.49 per
diluted share for the quarter ended June 30, 2006.  Net earnings as a
percentage of net sales improved from 37.4% in the fourth quarter of last
year to 39.2% for the quarter ended June 30, 2007.  For the fiscal year ended
June 30, 2007, Techne's consolidated net earnings increased 16.0% to $85.1
million or $2.15 per diluted share compared with $73.4 million or $1.85 per
diluted share for the fiscal year ended June 30, 2006.  Net earnings as a
percentage of net sales improved from 36.2% last year to 38.1% for fiscal
2007.  The improvement in net earnings was mainly due to increased
consolidated net sales.

Consolidated net sales for the quarter and fiscal year ended June 30, 2007
were $58.4 million and $223.5 million, respectively.  This was an increase of
12.2% and 10.3% from the fourth quarter and fiscal year ended June 30, 2006,
respectively. Fiscal 2007 net sales and earnings were favorably affected by
the strength of the British pound as compared to the U.S. dollar.  Excluding
the effect of changes in foreign currency exchange rates, consolidated net
sales increased 10.1% and 7.7% for the quarter and fiscal year ended June 30,
2007, respectively.

Biotechnology net sales, which include sales by R&D Systems' Biotechnology
Division, Fortron and BiosPacific, for the quarter and fiscal year ended June
30, 2007 were $38.1 million and $146.6 million, increases of 11.0% and 9.1%,
respectively, from the same prior-year periods.  R&D Europe's net sales for
the quarter and fiscal year were $16.2 million and $61.8 million, increases
of 20.1% and 16.6%, respectively, from the same prior-year periods.  In
British pound sterling, R&D Europe's net sales increased 12.0% and 6.6% for
the quarter and fiscal year ended June 30, 2007, respectively.  Hematology
net sales for the quarter and fiscal year were $4.1 million and $15.2
million, decreases of 2.7% and 0.9%, respectively.

Gross margins were 78.3% and 77.3% in the fourth quarter of fiscal 2007 and
2006, respectively, and 79.1% and 77.4% for the fiscal years 2007 and 2006,
respectively.  The improvement in gross margins resulted from lower cost of
goods sold related to inventories acquired from Fortron and BiosPacific that
were valued at fair market value under purchase accounting, higher margins in
Europe due to favorable exchange rates and changes in sales mix as a result
of sales growth in the Biotechnology Division as compared to sales declines
in the lower margin Hematology Division.  Fourth quarter fiscal 2007 margins
declined from the third quarter of fiscal 2007 mainly due to changes in
product mix and valuation estimates in the Biotechnology Division.

Selling, general and administrative expenses for the quarter and fiscal year
ended June 30, 2007 increased $1.6 million (25.1%) and $3.4 million (12.2%),
respectively. The fiscal year expense increase resulted from the change in
foreign currency exchange rates (approximately$750,000) and increases in
personnel and benefit costs, profit sharing and professional fee expenses.
Fourth quarter expenses increased approximately $600,000 from the third
quarter of fiscal 2007 due primarily to the timing of promotional marketing
costs (approximately $300,000) and increased profit sharing costs
(approximately $125,000).

The effective tax rate was 32.9% for the quarter ended June 30, 2007 as
compared to 35.2% for the prior quarter ended March 31, 2007.  The fourth
quarter fiscal 2007 effective tax rate was lower than in the third quarter of
fiscal 2007 due to changes in state apportionment estimates that were made in
the third quarter and a $420,000 reduction  in estimated tax contingency
reserves made in the fourth quarter.  The effective tax rate was 34.0% for
the fiscal years ended both June 30, 2006 and 2007.  Without significant
business developments, the Company expects its fiscal 2008 effective income
tax rate to range from approximately 33.5% to 34.5%.

The impact on consolidated net earnings of the change in exchange rates used
to convert R&D Europe results from British pounds to U.S. dollars was
approximately $368,000 ($.01 per diluted share) and $1.6 million ($.04 per
diluted share) for the quarter and fiscal year ended June 30, 2007,
respectively.

Forward Looking Statements:
This earnings release contains forward-looking statements within the meaning
of the Private Litigation Reform Act.  These statements, including the
Company's expectations as to income tax rates, involve risks and
uncertainties that may affect the actual results of operations. The following
important factors, among others, have affected and, in the future, could
affect the Company's actual results: the introduction and acceptance of new
biotechnology and hematology products, the levels and particular directions
of research by the Company's customers, the impact of the growing number of
producers of biotechnology research products and related price competition,
the retention of hematology OEM and proficiency survey business, the impact
of currency exchange rate fluctuations, and the costs and results of research
and product development efforts of the Company and of companies in which the
Company has invested or with which it has formed strategic relationships.
For additional information concerning such factors, see the Company's annual
report on Form 10-K and quarterly reports on Form 10-Q as filed with the
Securities and Exchange Commission.  We undertake no obligation to update or
revise any forward-looking statements we make in this release due to new
information or future events.  Investors are cautioned not to place undue
emphasis on these statements.

               *  *  *  *  *  *  *  *  *  *  *  *  *  *

Techne Corporation has two operating subsidiaries:  Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe,
Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has to subsidiaries,
BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D
Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific
is a worldwide supplier of biologics to manufacturers of in vitro diagnostic
systems and immunodiagnostic kits. R&D China and R&D Europe distribute
biotechnology products.

Contact:  Greg Melsen, Chief Financial Officer
          Kathy Backes, Controller
          612) 379-8854


                          TECHNE CORPORATION
                  CONSOLIDATED STATEMENTS OF EARNINGS
                 (In thousands, except per share data)
                             (Unaudited)
                                        QUARTER ENDED    FISCAL YEAR ENDED
                                       ----------------  ------------------
                                       6/30/07  6/30/06   6/30/07   6/30/06
                                       -------  -------  --------  --------
Net sales                              $58,425  $52,066  $223,482  $202,617
Cost of sales                           12,697   11,822    46,667    45,718
                                       -------  -------  --------  --------
Gross margin                            45,728   40,244   176,815   156,899
                                       -------  -------  --------  --------
Operating expenses:
 Selling, general and administrative     7,839    6,269    30,965    27,604
 Research and development                5,014    4,773    20,082    18,825
 Amortization of intangible assets         404      491     1,614     1,967
                                       -------  -------  --------  --------
   Total operating expenses             13,257   11,533    52,661    48,396
                                       -------  -------  --------  --------
Operating income                        32,471   28,711   124,154   108,503
Other expense (income):
 Interest expense                           --      258     1,083       964
 Interest income                        (2,565)  (1,522)   (8,434)   (4,708)
 Other non-operating expense, net          894      363     2,574     1,084
                                       -------  -------  --------  --------
   Total other income                   (1,671)    (901)   (4,777)   (2,660)
                                       -------  -------  --------  --------
Earnings before income taxes            34,142   29,612   128,931   111,163
Income taxes                            11,218   10,123    43,820    37,812
                                       -------  -------  --------  --------
Net earnings                           $22,924  $19,489  $ 85,111  $ 73,351
                                       =======  =======  ========  ========
Earnings per share:
 Basic                                 $  0.58  $  0.50  $   2.16  $   1.88
 Diluted                               $  0.58  $  0.49  $   2.15  $   1.85
Weighted average common
 shares outstanding:
 Basic                                  39,444   39,374    39,406    39,049
 Diluted                                39,555   39,487    39,513    39,594


                               TECHNE CORPORATION
                           CONSOLIDATED BALANCE SHEETS
                                 (In thousands)
                                  (Unaudited)
                                                  6/30/07   6/30/06
                                                 --------  --------
ASSETS
Cash and equivalents                             $135,485  $ 89,634
Short-term available-for-sale investments          29,289    19,212
Trade accounts receivable                          29,559    23,769
Other receivables                                   1,407     1,309
Inventory                                           8,757     9,024
Other current assets                                8,341     6,874
                                                 --------  --------
  Current assets                                  212,838   149,822

Available-for-sale investments                     91,433    77,660
Property and equipment, net                        91,535    88,772
Goodwill and intangible assets, net                30,167    32,021
Other non-current assets                           28,871    22,237
                                                 --------  --------
  Total assets                                   $454,844  $370,512
                                                 ========  ========
LIABILITIES
Current liabilities                              $ 17,193  $ 17,966
Long-term debt                                         --    12,198
Stockholders' equity                              437,651   340,348
                                                 --------  --------
  Total liabilities and equity                   $454,844  $370,512
                                                 ========  ========



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>segment607.txt
<DESCRIPTION>SEGMENT RESULTS
<TEXT>
                                SEGMENT INFORMATION
                        TECHNE CORPORATION AND SUBISIDARIES
                      (in thousands of $'s, except per share data)
<TABLE>
<CAPTION>
                                                                         Increase (Decrease)
                                  Fiscal 2007                              From Fiscal 2006
                ------------------------------------------------ --------------------------------------
                 First  Second   Third  Fourth          Percent   First  Second   Third  Fourth
                Quarter Quarter Quarter Quarter   YTD   Of Sales Quarter Quarter Quarter Quarter  YTD
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
<S>             <C>     <C>     <C>     <C>     <C>     <C>      <C>     <C>     <C>     <C>     <C>
Sales            52,351  52,509  60,197  58,425 223,482   100%     4,642   4,480   5,384   6,359 20,865
Cost of sales    11,237  10,714  12,019  12,697  46,667    21%       141      19     (86)    875    949
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Gross margin     41,114  41,795  48,178  45,728 176,815    79%     4,501   4,461   5,470   5,484 19,916

Gross margin
 percentage       78.5%   79.6%   80.0%   78.3%   79.1%

SG&A expense      7,067   8,830   7,229   7,839  30,965    14%       613     850     328   1,570  3,361
R&D expense       4,855   5,044   5,169   5,014  20,082     9%       138     470     408     241  1,257
Amortization
 expense            403     404     403     404   1,614     1%       (89)    (88)    (89)    (87)  (353)
Interest expense    268     815       0       0   1,083     0%        45     577    (245)   (258)   119
Interest income  (1,676) (1,956) (2,237) (2,565) (8,434)   (4%)     (702)   (826) (1,155) (1,043)(3,726)
Other non-opera-
 ting ex., net      485     428     767     894   2,574     1%       274     147     538     531  1,490
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
                 11,402  13,565  11,331  11,586  47,884    21%       279   1,130    (215)    954  2,148
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Earnings before
 income taxes    29,712  28,230  36,847  34,142 128,931    58%     4,222   3,331   5,685   4,530 17,768
Income taxes     10,081   9,567  12,954  11,218  43,820    20%     1,592   1,182   2,139   1,095  6,008
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
                 19,631  18,663  23,893  22,924  85,111    38%     2,630   2,149   3,546   3,435 11,760
                ======= ======= ======= ======= ======= ======== ======= ======= ======= ======= ======
Diluted earnings
 per share          .50     .47     .60     .58    2.15
Weighted average
 diluted shares
 outstanding     39,469  39,511  39,543  39,555  39,513

</TABLE>


                                     BIOTECHNOLOGY  (1)
                                     (in thousands of $'s)
<TABLE>
<CAPTION>
                                                                         Increase (Decrease)
                                  Fiscal 2007                              From Fiscal 2006
                ------------------------------------------------ --------------------------------------
                 First  Second   Third  Fourth          Percent   First  Second   Third  Fourth
                Quarter Quarter Quarter Quarter   YTD   Of Sales Quarter Quarter Quarter Quarter  YTD
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
<S>             <C>     <C>     <C>     <C>     <C>     <C>      <C>     <C>     <C>     <C>     <C>
Sales            41,621  40,073  46,202  44,788 172,684   100%     4,022   2,376   3,189   4,712 14,299
Intersegment
 sales           (5,699) (6,647) (7,072) (6,652)(26,070)            (400)    (92)   (676)   (941)(2,109)
                ------- ------- ------- ------- -------          ------- ------- ------- ------- ------
                 35,922  33,426  39,130  38,136 146,614            3,622   2,284   2,513   3,771 12,190

Cost of sales     8,482   7,683   9,041   9,577  34,783    20%        12    (464)    (84)    980    444
Intersegment
 sales           (5,524) (6,435) (7,147) (6,679)(25,785)            (201)   (295)   (669)   (922)(2,087)
                ------- ------- ------- ------- -------          ------- ------- ------- ------- ------
                  2,958   1,248   1,894   2,898   8,998             (189)   (759)   (753)     58 (1,643)

Gross margin     32,964  32,178  37,236  35,238 137,616    80%     3,811   3,043   3,266   3,713 13,833

Gross margin
 percentage       79.6%   80.8%   80.4%   78.6%   79.9%

SG&A expense     4,013    4,664   4,166   4,617  17,460    10%       374     470     (33)  1,207  2,018
R&D expense      4,675    4,854   4,971   4,833  19,333    11%       143     450     378     248  1,219
Amortization
 expense           403      404     403     404   1,614     2%       (89)    (88)    (89)    (87)  (353)
Interest, net     (595)    (722)   (841) (1,031) (3,189)   (2%)     (327)   (349)   (556)   (530)(1,762)
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
                  8,496   9,200   8,699   8,823  35,218    21%       101     483    (300)    838  1,122
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Pretax result    24,468  22,978  28,537  26,415 102,398    59%     3,710   2,560   3,566   2,875 12,711
                ======= ======= ======= ======= ======= ======== ======= ======= ======= ======= ======
</TABLE>

(1)  Includes R&D Systems' Biotechnology Division,
Fortron Bio Science, Inc., and BiosPacific, Inc.


                                      R&D SYSTEMS EUROPE
                                    (in thousands of British pounds)
<TABLE>
<CAPTION>
                                                                         Increase (Decrease)
                                  Fiscal 2007                              From Fiscal 2006
                ------------------------------------------------ --------------------------------------
                 First  Second   Third  Fourth          Percent   First  Second   Third  Fourth
                Quarter Quarter Quarter Quarter   YTD   Of Sales Quarter Quarter Quarter Quarter  YTD
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
<S>             <C>     <C>     <C>     <C>     <C>     <C>      <C>     <C>     <C>     <C>     <C>
Sales             6,870   7,851   8,854   8,154  31,729    100%      180     322     598     876  1,976
Cost of sales     3,285   3,766   4,091   3,797  14,939     47%       (7)      1    (100)    167     61
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Gross margin      3,585   4,085   4,763   4,357  16,790     53%      187     321     698     709  1,915

Gross margin
 percentage       52.2%   52.0%   53.8%   53.4%   52.9%

SG&A expense      1,074   1,236   1,075   1,113   4,498     14%       70      51       5      (2)   124
Interest income    (410)   (480)   (542)   (595) (2,027)    (6%)     (84)   (151)   (200)   (226)  (661)
Exchange loss
 /(gain)             78     (64)     22       6      42      --       63     (90)     71      15     59
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
                    742     692     555     524   2,513      8%       49    (190)   (124)   (213)  (478)
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Pretax result     2,843   3,393   4,208   3,833  14,277     45%      138     511     822     922  2,393
                ======= ======= ======= ======= ======= ======== ======= ======= ======= ======= ======
</TABLE>

                                          R&D SYSTEMS EUROPE
                                         (in thousands of $'s)
<TABLE>
<CAPTION>
                                                                         Increase (Decrease)
                                  Fiscal 2007                              From Fiscal 2006
                ------------------------------------------------ --------------------------------------
                 First  Second   Third  Fourth          Percent   First  Second   Third  Fourth
                Quarter Quarter Quarter Quarter   YTD   Of Sales Quarter Quarter Quarter Quarter  YTD
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
<S>             <C>     <C>     <C>     <C>     <C>     <C>      <C>     <C>     <C>     <C>     <C>
Sales            12,927  15,257  17,403  16,179  61,766    100%    1,052   2,151   2,907   2,702  8,812
Cost of sales     6,181   7,319   8,040   7,541  29,081     47%      337     765     682     818  2,602
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Gross margin      6,746   7,938   9,363   8,638  32,685     53%      715   1,386   2,225   1,884  6,210

Gross margin
 percentage       52.2%   52.0%   53.8%   53.4%   52.9%

SG&A expense      2,020   2,405   2,112   2,219   8,756     14%      238     346     233     155    972
Interest income    (771)   (933) (1,067) (1,174) (3,945)    (6%)    (192)   (361)   (467)   (494)(1,514)
Exchange loss
 /(gain)            147    (126)     42      19      82      --      119    (172)    129      36    112
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
                  1,396   1,346   1,087   1,064   4,893      8%      165    (187)   (105)   (303)  (430)
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Pretax result     5,350   6,592   8,276   7,574  27,792     45%      550   1,573   2,330   2,187  6,640
                ======= ======= ======= ======= ======= ======== ======= ======= ======= ======= ======
</TABLE>

                                             HEMATOLOGY
                                         (in thousands of $'s)
<TABLE>
<CAPTION>
                                                                         Increase (Decrease)
                                  Fiscal 2007                              From Fiscal 2006
                ------------------------------------------------ --------------------------------------
                 First  Second   Third  Fourth          Percent   First  Second   Third  Fourth
                Quarter Quarter Quarter Quarter   YTD   Of Sales Quarter Quarter Quarter Quarter  YTD
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
<S>             <C>     <C>     <C>     <C>     <C>     <C>      <C>     <C>     <C>     <C>     <C>
Sales             3,502   3,826   3,664   4,110  15,102    100%      (32)     45     (36)   (114)  (137)
Cost of sales     2,098   2,147   2,085   2,258   8,588     57%       (7)     13     (15)     (1)   (10)
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Gross margin      1,404   1,679   1,579   1,852   6,514     43%      (25)     32     (21)   (113)  (127)

Gross margin
 percentage       40.1%   43.9%   43.1%   45.1%   43.1%

SG&A expense        398     439     431     422   1,690     11%       14      15     (10)     46     65
R&D expense         180     190     198     181     749      5%       (5)     20      30      (7)    38
Interest, net       (81)    (95)   (111)   (136)   (423)    (3%)     (44)    (45)    (71)    (62)  (222)
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
                    497     534     518     467   2,016     13%      (35)    (10)    (51)    (23)  (119)
                ------- ------- ------- ------- ------- -------- ------- ------- ------- ------- ------
Pretax result       907   1,145   1,061   1,385   4,498     30%       10      42      30     (90)    (8)
                ======= ======= ======= ======= ======= ======== ======= ======= ======= ======= ======
</TABLE>


                                   CORPORATE AND OTHER (2)
                                  (in thousands of $'s)
<TABLE>
<CAPTION>
                                                                   Increase (Decrease)
                                  Fiscal 2007                       From Fiscal 2006
                --------------------------------------- --------------------------------------
                 First  Second   Third  Fourth           First  Second   Third  Fourth
                Quarter Quarter Quarter Quarter   YTD   Quarter Quarter Quarter Quarter  YTD
                ------- ------- ------- ------- ------- ------- ------- ------- ------- ------
<S>             <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
Interest income     229     206     218     224     877     139      71      61     (43)   228
Rental income       299     241      55      91     686     (43)    (96)   (232)   (229)  (600)
                ------- ------- ------- ------- ------- ------- ------- ------- ------- ------
                    528     447     273     315   1,563      96     (25)   (171)   (272)  (372)

SG&A expense        636   1,322     520     581   3,059     (13)     19     138     162    306
Interest expense    268     815       0       0   1,083      45     577    (245)   (258)   119
Other-Building
 expenses           510     549     519     634   2,212      67      59      (1)    105    230
Other-Hemerus
 losses             127     123     119     169     538      45      41      36      (2)   120
Other-Nephromics
 losses              --     123     142     163     428      --     123     142     163    428
                ------- ------- ------- ------- ------- ------- ------- ------- ------- ------
                  1,541   2,932   1,300   1,547   7,320     144     819      70     170  1,203
                ------- ------- ------- ------- ------- ------- ------- ------- ------- ------
Pretax result    (1,013) (2,485) (1,027) (1,232) (5,757)    (48)   (844)   (241)   (442)(1,575)
                ======= ======= ======= ======= ======= ======= ======= ======= ======= ======
</TABLE>


(2)  Unallocated corporate expenses and Techne's share
of losses by Hemerus Medical, LLC and Nephromics, LLC.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
